Safe management of adverse effects associated with prescription opioids in the palliative care population: a narrative review 

Zimmerman A, et al. J Clin Med. 2024

Impact of patient subgroups on the efficacy and safety of methylnaltrexone for opioid-induced constipation in patients with advanced illness

Mehta N, et al. J Pain Res. 2023

Response rates to methylnaltrexone in hospitalized cancer patients

Harris D, et al. Am J Hosp Palliat Care. 2023

Management of constipation in hospitalized patients

Sayuk GS, et al. J Clin Med. 2023

Methylnaltrexone treatment for opioid-induced constipation in patients with and without cancer: effect of initial dose

Chamberlain BH, et al. J Pain Res. 2023

Methylnaltrexone for opioid induced dysmotility in critically ill infants and children: a pilot study

Smith CJ, et al. J Pediatr Pharmacol Ther. 2023

Reductions in all-cause mortality associated with the use of methylnaltrexone for opioid-induced bowel disorders: a pooled analysis

Webster LR, et al. Pain Med. 2023

Subcutaneous methylnaltrexone as treatment for opioid-induced constipation in patients with advanced cancer and noncancer illnesses: a post hoc analysis of two clinical trials

Shah ED, et al. J Pain Res. 2023

Cumulative laxation response with methylnaltrexone: implications for hospitalized patients with advanced illness and opioid-induced constipation

Farchadi D, et al. Curr Ther Res Clin Exp. 2023

First-dose efficacy of methylnaltrexone in patients with severe medical illness and opioid-induced constipation: a pooled analysis

Peacock WF, et al. Journal of Emergency Medicine. 2022.

Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials 

Mehta N, et al. F1000 Research. 2021.

Efficacy and safety of peripherally acting μ-opioid receptor antagonist (PAMORAs) for the management of patients with opioid-induced constipation: a systematic review

Rekatsina M, et al. Cureus. 2021.

The influence of age on central effects of methylnaltrexone in patients with opioid-induced constipation 

Liao SS, et al. Drugs & Aging. 2021.

Management of opioid-induced and non-opioid-related constipation in patients with cancer: systematic review and meta-analysis 

Ginex PK, et al. Oncology Nursing Forum. 2020.

Efficacy and safety of peripherally acting mu-opioid receptor antagonists for the treatment of opioid-induced constipation: a Bayesian network meta-analysis 

Ouyang R, et al. Pain Medicine. 2020.

Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation 

Vijayvargiya P, et al. Alimentary Pharmacology and Therapeutics. 2020.

Methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients. Results from the MOTION trial 

Patel PB, et al. Intensive Care Medicine. 2020.

Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer 

Chamberlain BH, et al. Pain Management. 2020.

Identifying and treating opioid side effects: the development of methylnaltrexone 

Moss J. Anesthesiology. 2019.

Pharmacological treatment of opioid-induced constipation is effective but choice of endpoints affects the therapeutic gain

Nusrat S, et al. Digestive Diseases and Sciences. 2019.

Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis 

Nee J, et al. Clinical Gastroenterology and Hepatology. 2018.

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care 

Candy B, et al. Cochrane Database of Systematic Reviews. 2018.

Drugs for treating opioid-induced constipation: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials 

Sridharan K, et al. Journal of Pain and Symptom Management. 2018.

Long-term safety and efficacy of subcutaneous methylnaltrexone in patients with opioid-induced constipation and chronic noncancer pain: a phase 3, open-label trial 

Webster LR, et al. Pain Medicine. 2017.

Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study 

Mori M, et al. International Journal of Clinical Oncology. 2017.

Protocol for a randomised control trial of methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients (MOTION) 

Patel PB, et al. BMJ Open. 2016.

Efficacy and safety of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain: a placebo crossover analysis 

Viscusi ER, et al. Regional Anesthesia & Pain Medicine. 2016.

Efficacy of methylnaltrexone for the treatment of opioid-induced constipation: a meta-analysis and systematic review 

Mehta N, et al. Postgraduate Medicine. 2016.

Efficacy and tolerability of subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: a responder analysis of 2 randomized, placebo-controlled trials

Nalamachu SR, et al. Pain Practice. 2015.

Advances in pharmacotherapy for opioid-induced constipation - a systematic review 

Siemens W, et al. Expert Opinion on Pharmacotherapy. 2015.

Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis

Ford AC, et al. The American Journal of Gastroenterology. 2013.

Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery 

Anissian L, et al. Journal of Hospital Medicine. 2012.

Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials 

Slatkin NE, et al. Journal of Pain Symptom Management. 2011.

Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis 

Michna E, et al. Pain Medicine. 2011.

Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study 

Michna E, et al. Journal of Pain. 2011.

Laxatives or methylnaltrexone for the management of constipation in palliative care patients 

Candy B, et al. Cochrane Database of Systematic Reviews. 2011.

Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms 

Iyer SS, et al. Value in Health. 2011.

Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study 

Lipman AG, et al. Journal of Pain & Palliative Care Pharmacotherapy. 2011.

Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness 

Chamberlain BH, et al. Journal of Pain and Symptom Management. 2009.

Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients 

Slatkin NE, et al. Journal of Supportive Oncology. 2009.

Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials

McNicol ED, et al. Pain Medicine. 2008.

Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study 

Portenoy RK, et al. Journal of Pain Symptom Management. 2008.

Methylnaltrexone for opioid-induced constipation in advanced illness 

Thomas J, et al. New England Journal of Medicine. 2008.

Mu-opioid antagonists for opioid-induced bowel dysfunction

McNicol ED, et al. Cochrane Database of Systematic Reviews. 2008.

Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review 

Becker G, et al. Journal of Pain and Symptom Management. 2007.

Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial 

Yuan CS, et al. Journal of Pharmacology & Experimental Therapeutics. 2002.